About HemaMax™

The therapeutic under development by Neumedicines Inc., HemaMax™, is based on rHuIL-12 (Recombinant Human Interleukin – 12).  Scientists from Neumedicines Inc. discovered the previously unknown hematological properties of IL-12 by demonstrating the potent survival effects of single, low dose IL-12 on hematopoietic recovery following lethal irradiation in mice.

Neumedicines has demonstrated that IL-12 can rescue mice from otherwise lethal doses of radiation utilizing low doses administered post irradiation at time points of 3 hours (60% survival at 9Gy), 6 hours (100% survival at 8Gy) and 24 hours (90% survival at 8Gy).

Neumedicines is currently working to demostrate the protective benefits conferred by IL-12 in humans.

Neumedicines believes at the present time that the administration of IL-12 post radiation exposure, including time points of 24 hours or longer, will prove to provide significant protective functions for the human hematopoietic system by not only mitigating the bone marrow damage caused by acute ionizing radiation, but also as a therapeutic that is capable of complete regeneration of multilineage hematopoiesis following lethal radiation exposure.